ID   WM902B
AC   CVCL_6807
SY   WM-902B; WM 902B; WM 902 B; WML 902B; WM902; WC00083
DR   BTO; BTO:0005780
DR   cancercelllines; CVCL_6807
DR   Coriell; WC00083
DR   Cosmic; 686398
DR   Cosmic; 972273
DR   Cosmic; 1155282
DR   Cosmic; 1155553
DR   Cosmic; 1187581
DR   Cosmic; 2163812
DR   Cosmic; 2838886
DR   ESTDAB; ESTDAB-085
DR   GDSC; 1240227
DR   GEO; GSM186501
DR   GEO; GSM186502
DR   GEO; GSM952591
DR   PharmacoDB; WM902B_1674_2019
DR   Progenetix; CVCL_6807
DR   Rockland; WM902B-01-0001
DR   Wikidata; Q54994340
RX   PubMed=2068080;
RX   PubMed=2253310;
RX   PubMed=4053039;
RX   PubMed=15592718;
RX   PubMed=18632627;
RX   PubMed=18790768;
RX   PubMed=21156289;
RX   PubMed=23851445;
RX   PubMed=27500726;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*01:01,29:01; B*07:02,08:01; C*07:01:01,15:05; DPB1*04:01,02:01:02; DQB1*03:01:01,04:02; DRB1*08:01,11:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=18632627; PubMed=21156289; PubMed=23851445; Wistar).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Leu (c.71G>T); ClinVar=VCV000376377; Zygosity=Unspecified (PubMed=21156289; PubMed=23851445; Wistar).
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: Coriell; WC00083; probable.
CC   Discontinued: ESTDAB; ESTDAB-085; probable.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): Wistar
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 11,13
ST   D19S433: 12,13
ST   D21S11: 28,30
ST   D2S1338: 17,24
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 12,14
ST   FGA: 19
ST   TH01: 6,8
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B.,
RA   Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P.,
RA   Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//
RX   PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023;
RA   Villanueva J., Vultur A., Lee J.T., Somasundaram R.,
RA   Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W.,
RA   Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K.,
RA   Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A.,
RA   Sosman J.A., Nathanson K.L., Herlyn M.;
RT   "Acquired resistance to BRAF inhibitors mediated by a RAF kinase
RT   switch in melanoma can be overcome by cotargeting MEK and
RT   IGF-1R/PI3K.";
RL   Cancer Cell 18:683-695(2010).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=27500726; DOI=10.1038/nm.4155;
RA   Shen C.-H., Kim S.H., Trousil S., Frederick D.T., Piris A., Yuan P.,
RA   Cai L., Gu L., Li M., Lee J.H., Mitra D., Fisher D.E., Sullivan R.J.,
RA   Flaherty K.T., Zheng B.;
RT   "Loss of cohesin complex components STAG2 or STAG3 confers resistance
RT   to BRAF inhibition in melanoma.";
RL   Nat. Med. 22:1056-1061(2016).
//